Business context and reporting period
Adagene Inc. is a Cayman Islands holding company and clinical-stage biopharmaceutical company developing antibody-based cancer immunotherapies. It conducts substantial operations through subsidiaries in China and the United States. Its proprietary Dynamic Precision Library platform supports its NEObody, SAFEbody and POWERbody technologies. The filing is an audited Form 20-F for the fiscal year ended December 31, 2021, prepared under U.S. GAAP; it is not a standalone Q4 report, and separate Q4 financial results are not provided in the filing text.
The company had no approved products and generated no product-sales revenue. Its wholly owned clinical-stage candidates ADG116, ADG126 and ADG106 were in clinical development; other candidates were in preclinical development. ADSs trade on Nasdaq as ADAG, with each ADS representing 1.25 ordinary shares.
Key financial metrics
| Metric | FY 2021 | FY 2020 | Change or context |
|---|---|---|---|
| Licensing and collaboration revenue | US$10.2 million | US$0.7 million | Increase primarily reflected Exelixis collaboration revenue and a Dragon Boat milestone; no product sales |
| Research and development expense | US$68.1 million | US$33.5 million | Up 103%; increased personnel, clinical and preclinical work, and CMC activity |
| Administrative expense | US$14.4 million | US$10.3 million | Up 40%, including higher personnel and professional costs |
| Operating loss | US$72.4 million | US$43.2 million | Loss widened as operating expenses rose |
| Net loss attributable to shareholders | US$73.2 million | US$42.4 million | Loss widened 72.6%; FY 2021 includes US$1.7 million income tax expense |
| Net loss per ordinary share, basic and diluted | US$1.46 | US$2.67 | Per-share loss declined as weighted-average shares increased substantially after the IPO |
| Operating cash used | US$43.4 million | US$28.5 million | Cash use increased |
| Cash and cash equivalents at year-end | US$174.4 million | US$75.2 million | Higher principally due to the February 2021 IPO |
| Total borrowings | US$7.5 million | US$8.0 million | Mostly bank loans; no collateral or loan covenants disclosed |
Gross margin and product margins are not meaningful for this pre-commercial company; the filing does not provide a clear product-margin measure. FY 2021 investing cash use was US$2.5 million, principally for property, equipment and software. Financing generated US$145.4 million, mainly from the IPO. Year-end current assets were US$186.0 million and current liabilities US$29.8 million.
Management stated that available cash and expected proceeds from financing and collaborations should fund current and anticipated working-capital needs and capital expenditures for at least 12 months from the filing’s assessment, while cautioning that estimates could prove wrong. The company reported an accumulated deficit of US$178.8 million and expects continued significant losses and operating expenses.
Material changes, outlook and commentary
- Revenue growth was collaboration-driven rather than product-driven. Exelixis accounted for US$8.5 million of FY 2021 recognized revenue; Dragon Boat revenue was also recognized following milestone achievement. A US$3.0 million Exelixis milestone receivable was collected in January 2022.
- The February 2021 IPO generated approximately US$145.9 million of net proceeds. The company reported using US$31 million of IPO proceeds through year-end, primarily for research and development. It repurchased 236,139 ADSs during 2021 for approximately US$2.4 million under a program authorizing up to US$20 million.
- After year-end, Adagene signed a Sanofi collaboration and license agreement and received a US$17.5 million upfront payment in April 2022. The agreement provides for potential development, regulatory and commercial milestones of up to US$2.5 billion plus tiered royalties; these are contingent, not guaranteed revenue.
- Clinical progress remained early-stage. ADG116 had a prior U.S. Phase 1 clinical hold in 2019 after a patient death; the hold was lifted after protocol changes. In the later trial, the company reported one dose-limiting event at 10 mg/kg as of March 31, 2022. ADG126 had no reported dose-limiting toxicities in its ongoing monotherapy escalation through March 31, 2022. ADG106 completed two Phase 1 monotherapy trials; reported responses were preliminary and included one partial response and stable disease in some patients.
- Management identified COVID-19 as a potential source of clinical-trial, enrollment, laboratory and supply disruption. It also highlighted reliance on third parties, including WuXi Biologics for clinical manufacturing, and reported US$10.3 million payable to WuXi Biologics at year-end, a related party whose controlling party is associated with a principal shareholder.
- Key risks include clinical safety and efficacy uncertainty, funding needs, competition, intellectual-property protection, dependence on partners and contract manufacturers, and PRC regulatory, data-transfer and foreign-exchange restrictions. The PCAOB had determined it could not fully inspect or investigate the company’s auditor; the filing warned of potential HFCA Act trading prohibition and delisting risk. The company also described uncertainty around proposed PRC rules for overseas listings.
- Management said previously identified internal-control material weaknesses had been remediated and internal control over financial reporting was effective as of December 31, 2021. The auditor did not attest to that assessment under the applicable transition-period exemption. No material legal proceedings were reported.
Most important facts for investors to verify
- Whether cash burn, collaboration receipts and remaining cash support the stated minimum 12-month funding outlook, and how much cash is available for use across jurisdictions.
- Clinical-trial updates for ADG116, ADG126 and ADG106, including full safety data, confirmed efficacy endpoints, trial enrollment and the status of combination studies.
- Recognition, collection and timing of collaboration payments, especially the contingent Sanofi and Exelixis milestones, royalty terms, partner options and termination rights.
- Related-party service spending and balances, including WuXi Biologics purchases and payables, and any manufacturing concentration or supply alternatives.
- Developments in PCAOB inspection access, HFCA Act listing status and PRC approvals or filing requirements affecting overseas securities offerings and cross-border data.
- Potential dilution from equity awards and future financing, and execution and cash impact of the share-repurchase program.